MX2014005458A - Inhibidor doble de met y del factor de crecimiento endotelial vascular (vegf) para el tratamiento del cáncer. - Google Patents
Inhibidor doble de met y del factor de crecimiento endotelial vascular (vegf) para el tratamiento del cáncer.Info
- Publication number
- MX2014005458A MX2014005458A MX2014005458A MX2014005458A MX2014005458A MX 2014005458 A MX2014005458 A MX 2014005458A MX 2014005458 A MX2014005458 A MX 2014005458A MX 2014005458 A MX2014005458 A MX 2014005458A MX 2014005458 A MX2014005458 A MX 2014005458A
- Authority
- MX
- Mexico
- Prior art keywords
- vegf
- met
- treating cancer
- dual inhibitor
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 229940125436 dual inhibitor Drugs 0.000 title abstract 2
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
- 101150030763 Vegfa gene Proteins 0.000 title 1
- 206010027452 Metastases to bone Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161557358P | 2011-11-08 | 2011-11-08 | |
| PCT/US2012/064116 WO2013070890A1 (en) | 2011-11-08 | 2012-11-08 | Dual inhibitor of met and vegf for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014005458A true MX2014005458A (es) | 2015-04-16 |
Family
ID=47179011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014005458A MX2014005458A (es) | 2011-11-08 | 2012-11-08 | Inhibidor doble de met y del factor de crecimiento endotelial vascular (vegf) para el tratamiento del cáncer. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20140323522A1 (enExample) |
| EP (1) | EP2776033A1 (enExample) |
| JP (2) | JP2014532766A (enExample) |
| KR (1) | KR20140088610A (enExample) |
| CN (1) | CN104159585A (enExample) |
| AU (2) | AU2012335737A1 (enExample) |
| BR (1) | BR112014011009A2 (enExample) |
| CA (1) | CA2854336A1 (enExample) |
| EA (1) | EA201490944A1 (enExample) |
| HK (1) | HK1202062A1 (enExample) |
| IL (1) | IL232421A0 (enExample) |
| IN (1) | IN2014CN04067A (enExample) |
| MX (1) | MX2014005458A (enExample) |
| TW (2) | TWI662962B (enExample) |
| WO (1) | WO2013070890A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| HUE045810T2 (hu) | 2010-09-27 | 2020-01-28 | Exelixis Inc | MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére |
| TW201309650A (zh) | 2011-02-10 | 2013-03-01 | 艾克塞里克斯公司 | 製造喹啉化合物之方法及包含該化合物之醫藥組合物 |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| EP2704717A1 (en) | 2011-05-02 | 2014-03-12 | Exelixis, Inc. | Method of treating cancer and bone cancer pain |
| GEP201606523B (en) | 2011-09-22 | 2016-08-10 | Exelixis Inc | Method for treating osteoporosis |
| PL2768796T3 (pl) | 2011-10-20 | 2020-05-18 | Exelixis, Inc. | Sposób wytwarzania pochodnych chinoliny |
| HK1207587A1 (en) | 2012-05-02 | 2016-02-05 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| GEP20196995B (en) | 2013-03-15 | 2019-07-25 | Inc Exelixis | Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
| ES2927651T3 (es) | 2013-04-04 | 2022-11-10 | Exelixis Inc | Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer |
| US9149471B2 (en) * | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
| EA032757B1 (ru) | 2014-02-14 | 2019-07-31 | Экселиксис, Инк. | Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения |
| CN106255499A (zh) | 2014-03-17 | 2016-12-21 | 埃克塞里艾克西斯公司 | 卡博替尼制剂的给药 |
| CN104788372B (zh) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体 |
| EA033834B1 (ru) | 2014-07-31 | 2019-11-29 | Exelixis Inc | Способ получения кабозантиниба, меченного фтором-18, и его аналогов |
| MA40457A (fr) | 2014-08-05 | 2017-06-14 | Exelixis Inc | Combinaison de médicaments pour traiter le myélome multiple |
| CN105503717A (zh) * | 2014-09-24 | 2016-04-20 | 江苏奥赛康药业股份有限公司 | 一种苹果酸卡博替尼化合物及其药物组合物 |
| US11141413B2 (en) | 2016-04-15 | 2021-10-12 | Exelixis, Inc. | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
| US10723701B2 (en) * | 2016-10-18 | 2020-07-28 | Beijing Konruns Pharmaceutical Co., Ltd. | Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same |
| MX2019012505A (es) | 2017-05-26 | 2019-12-19 | Exelixis Inc | Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso. |
| HRP20251184T1 (hr) | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| TWI787523B (zh) | 2018-06-15 | 2022-12-21 | 漢達生技醫藥股份有限公司 | 達沙替尼十二烷基硫酸鹽之結晶 |
| KR20250136810A (ko) | 2023-01-31 | 2025-09-16 | 한다 온콜로지, 엘엘씨 | 개선된 카보잔티닙 조성물 및 사용 방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| WO2008083319A1 (en) | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of enantiopure ilaprazole |
| UA108618C2 (uk) * | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| HUE045810T2 (hu) * | 2010-09-27 | 2020-01-28 | Exelixis Inc | MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére |
| WO2012044577A1 (en) * | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
-
2012
- 2012-11-08 MX MX2014005458A patent/MX2014005458A/es unknown
- 2012-11-08 EP EP12787328.9A patent/EP2776033A1/en not_active Ceased
- 2012-11-08 KR KR1020147015127A patent/KR20140088610A/ko not_active Ceased
- 2012-11-08 TW TW101141696A patent/TWI662962B/zh active
- 2012-11-08 US US14/356,927 patent/US20140323522A1/en not_active Abandoned
- 2012-11-08 EA EA201490944A patent/EA201490944A1/ru unknown
- 2012-11-08 CA CA2854336A patent/CA2854336A1/en not_active Abandoned
- 2012-11-08 IN IN4067CHN2014 patent/IN2014CN04067A/en unknown
- 2012-11-08 HK HK15102604.7A patent/HK1202062A1/xx unknown
- 2012-11-08 AU AU2012335737A patent/AU2012335737A1/en not_active Abandoned
- 2012-11-08 JP JP2014541256A patent/JP2014532766A/ja active Pending
- 2012-11-08 CN CN201280066410.5A patent/CN104159585A/zh active Pending
- 2012-11-08 WO PCT/US2012/064116 patent/WO2013070890A1/en not_active Ceased
- 2012-11-08 BR BR112014011009A patent/BR112014011009A2/pt not_active IP Right Cessation
- 2012-11-08 TW TW106131943A patent/TW201818937A/zh unknown
-
2014
- 2014-05-01 IL IL232421A patent/IL232421A0/en unknown
-
2017
- 2017-09-08 AU AU2017225103A patent/AU2017225103A1/en not_active Abandoned
- 2017-10-04 JP JP2017193945A patent/JP2018048154A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012335737A1 (en) | 2014-06-05 |
| CA2854336A1 (en) | 2013-05-16 |
| EA201490944A1 (ru) | 2014-10-30 |
| CN104159585A (zh) | 2014-11-19 |
| US20140323522A1 (en) | 2014-10-30 |
| EP2776033A1 (en) | 2014-09-17 |
| HK1202062A1 (en) | 2015-09-18 |
| TW201818937A (zh) | 2018-06-01 |
| IL232421A0 (en) | 2014-06-30 |
| TWI662962B (zh) | 2019-06-21 |
| KR20140088610A (ko) | 2014-07-10 |
| JP2014532766A (ja) | 2014-12-08 |
| AU2017225103A1 (en) | 2017-09-28 |
| IN2014CN04067A (enExample) | 2015-10-23 |
| TW201322981A (zh) | 2013-06-16 |
| JP2018048154A (ja) | 2018-03-29 |
| BR112014011009A2 (pt) | 2017-06-06 |
| WO2013070890A1 (en) | 2013-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013003594A (es) | Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis de osteoblasticas en los huesosl. | |
| HK1202062A1 (en) | Dual inhibitor of met and vegf for treating cancer | |
| HK1207587A1 (en) | A dual met - vegf modulator for treating osteolytic bone metastases | |
| MX2015002947A (es) | Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo. | |
| IL304337A (en) | Antiandrogens for the treatment of castration-resistant prostate cancer without metastases | |
| MX2013015158A (es) | Compuestos inhibidores de metaloenzima. | |
| PH12014502047B1 (en) | Treatment of cancer with tor kinase inhibitors | |
| BR112013024211A2 (pt) | tratamento de tumores sólidos | |
| PH12015500867A1 (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| PH12014502461A1 (en) | Biomarkers for iap inhibitor therapy | |
| HK1187831A (en) | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases | |
| HK1187832A (en) | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |